However, given that LAP is known to be involved in anti-inflammatory pathways such as the efferocytosis of apoptotic bodies and the anti-microbial clearance of bacterial and fungal infections, systematically targeting the LAP PI3KC3 complex could have undesirable side effects that result in chronic inflammation and prolonged infections. Here, TGFB1 is linked to infection.